CMC Biologics appoints new CEO

Gustavo Mahler, COO & President at CMC Biologics, to Take the Helm January 1st 2016

22-Oct-2015 - Denmark

CMC Biologics, Inc. announced the promotion of Gustavo Mahler, to be effective January 1st 2016, to serve as its Chief Executive Officer.

Gustavo has more that 20 years of executive management experience in biologics manufacturing and development. Gustavo joined the company as head of the Seattle facility in 2008. He was promoted to President of US operations and then became the COO for the Company’s global operations.

“This transition of Gustavo taking over the CEO responsibility from Claes Glassell has been planned for a long time. We are excited that Gustavo can continue the leadership of the Company through a seamless transition. Claes has been with CMC Biologics for more than 10 years, first as a board director and as CEO since 2011. He will continue as a board director and we are grateful for his commitment and the industrial experience he brought to the company. Claes will continue to assist CMC Biologics in its growth and continued success,” said David Kauffmann, Chairman of the Board of CMC Biologics, and Managing Partner of European Equity Partners.

Prior to joining CMC Biologics, Gustavo was head of manufacturing at the Bayer Healthcare biotechnology plant in Berkeley, California. Gustavo worked for 15 years at Bayer in the United States, Europe and Latin America serving in various manufacturing and management positions. He received his PhD in biochemistry from the University of Buenos Aires, and has a Master of Business Administration degree from the University UNED of Madrid and an Executive Certification in Management from MIT Sloan.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances